US Patent

US10456360 — Stabilizing camptothecin pharmaceutical compositions

Formulation · Assigned to Ipsen Biopharm Ltd · Expires 2036-10-15 · 10y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a formulation of irinotecan (Camptosar) in the form of phospholipid liposomes with improved storage stability.

USPTO Abstract

Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.

Drugs covered by this patent

Patent Metadata

Patent number
US10456360
Jurisdiction
US
Classification
Formulation
Expires
2036-10-15
Drug substance claim
No
Drug product claim
Yes
Assignee
Ipsen Biopharm Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.